Showing results (51-60 of 70) with videos related to
Sort By:
Pageof 7
Journal of the National Cancer Institute|April 22, 2015
Germline TP53 variants and susceptibility to osteosarcomaLisa Mirabello, Meredith Yeager, Phuong L Mai, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 1, 2009
Ae2(a,b)-deficient mice exhibit osteopetrosis of long bones but not of calvariaIneke D C Jansen, Pablo Mardones, Fernando Lecanda, et al.Signal Transduction and Targeted Therapy|June 12, 2025
Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancerBorja Ruiz-Fernández de Córdoba, Karmele Valencia, Connor Welch, et al.Molecular Cancer|May 20, 2023
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancerRodrigo Entrialgo-Cadierno, Cristina Cueto-Ureña, Connor Welch, et al.Nature Communications|February 22, 2017
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancerAdrian Vallejo, Naiara Perurena, Elisabet Guruceaga, et al.The Journal of Clinical Investigation|December 25, 2019
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreasKarmele Valencia, Oihane Erice, Kaja Kostyrko, et al.Journal of Hepatology|April 22, 2021
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targetedAdrián Vallejo, Oihane Erice, Rodrigo Entrialgo-Cadierno, et al.Nature Cancer|February 5, 2022
Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockadeDaniel Ajona, Sergio Ortiz-Espinosa, Teresa Lozano, et al.American Journal of Respiratory and Critical Care Medicine|June 6, 2019
YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to DasatinibIrati Garmendia, María J Pajares, Francisco Hermida-Prado, et al.Nature Communications|October 10, 2023
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancerIrati Macaya, Marta Roman, Connor Welch, et al.Pageof 7